NASDAQ:EPZM - Epizyme Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.93 +0.47 (+3.77 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$12.93
Today's Range$12.4150 - $13.05
52-Week Range$5.14 - $18.65
Volume1.05 million shs
Average Volume853,745 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.08
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.70 million
Book Value$3.64 per share

Profitability

Net Income$-123,630,000.00

Miscellaneous

Employees124
Market Cap$1.17 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) released its earnings results on Monday, May, 6th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.07. The biopharmaceutical company earned $7.89 million during the quarter, compared to the consensus estimate of $1.13 million. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

8 Wall Street analysts have issued twelve-month price targets for Epizyme's stock. Their predictions range from $11.00 to $25.00. On average, they expect Epizyme's share price to reach $18.50 in the next year. This suggests a possible upside of 43.1% from the stock's current price. View Analyst Price Targets for Epizyme.

What is the consensus analysts' recommendation for Epizyme?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Has Epizyme been receiving favorable news coverage?

Media headlines about EPZM stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Epizyme earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)

Who are Epizyme's major shareholders?

Epizyme's stock is owned by many different of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (11.29%), Redmile Group LLC (8.47%), BlackRock Inc. (5.38%), FMR LLC (3.84%), Victory Capital Management Inc. (1.80%) and Opaleye Management Inc. (1.50%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Voya Investment Management LLC, Marshall Wace LLP, BlackRock Inc., Spark Investment Management LLC, Citigroup Inc., Morgan Stanley and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Epizyme.

Which institutional investors are buying Epizyme stock?

EPZM stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Redmile Group LLC, Primecap Management Co. CA, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., Opaleye Management Inc., Geode Capital Management LLC and Oxford Asset Management LLP. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $12.93.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.17 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is http://www.epizyme.com/.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (NASDAQ EPZM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  669
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel